Youth Substance Use Trends: Highest Rates in History

Aug.24.2022
Youth Substance Use Trends: Highest Rates in History
Marijuana and nicotine e-cigarette usage among young people hit historic highs in 2021, according to a report.

According to a report released by the National Institute on Drug Abuse in the United States, in 2021, the usage rates of cannabis and nicotine electronic cigarettes among young people reached an all-time high level.


Dr. Megan E. Patrick and her colleagues at the University of Michigan's Institute for Social Research in Ann Arbor studied drug use prevalence and trends among young people dating back to 1975 in a monitoring group study. Participants were initially sampled in 12th grade at the age of 18, and then surveyed annually until the age of 30.


Researchers have found that in 2021, the most commonly used substances among young people in the past 12 months were alcohol, marijuana, nicotine e-cigarettes, marijuana e-cigarettes, cigarettes, and other drugs (at 81.8%, 42.6%, 21.8%, 18.7%, and 18.3% respectively). The report showed a binge-drinking rate of 32.0% and a daily marijuana use rate of 10.8%. From 2020 to 2021, there was an increase in monthly marijuana e-cigarette use, a decrease in daily alcohol consumption but an increase in binge drinking, returning to the pre-pandemic levels of 2019. There was also an increase in monthly nicotine e-cigarette use, a decrease in non-medical use of narcotics other than heroin, and a decrease in non-medical use of some stimulants, including amphetamines, Adderall, cocaine, and methamphetamine.


In 2021, there was a high prevalence of cannabis, nicotine e-cigarettes, high-intensity alcohol, and hallucinogens other than LSD within a month, while smoking, excessive drinking, and the use of anesthetics other than heroin, Vicodin, and Oxycodone were at historically low levels.


Dr. Nora Volkow, Director of the National Institute on Drug Abuse, stated in a press release that "understanding how drug use affects young adults' future choices is crucial in helping the next generation avoid harm.


This article contains excerpts or reposts from third-party sources, and their copyright belongs to the original media and authors. If there is any infringement, please contact us for deletion. Any individuals or organizations who wish to repost must contact the author and refrain from reposting directly.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
A Fifth Circuit panel upheld the U.S. Food and Drug Administration’s 2021 final rule requiring companies seeking premarket authorization for new tobacco products to include information on health-risk investigations. In a published opinion, the court found FDA satisfied the Regulatory Flexibility Act’s procedural requirements and reasonably relied on the economic analysis from the 2016 “deeming rule” as a factual basis to certify limited impact on small businesses.
Feb.27 by 2FIRSTS.ai
Special Report|FDA Revises Device Name in Glas Vape Authorization; Company Signals Optimism on Menthol, Flavored Pods
Special Report|FDA Revises Device Name in Glas Vape Authorization; Company Signals Optimism on Menthol, Flavored Pods
The FDA updated public records on the PMTA authorization of a Glas vape product, renaming “Glas G Device” to “Glas G² Device” and releasing the order letter detailing scientific review and marketing restrictions. Company disclosures suggest the platform may include age-verification technology. If confirmed, Glas G² could be the first vape with device-level age verification to receive an FDA MGO. Glas executives also said menthol and other flavored pods could gain authorization in the future.
Special Report
Mar.14
PMI U.S. to Invest About USD 50 Million in New Business Solutions Center in Tampa
PMI U.S. to Invest About USD 50 Million in New Business Solutions Center in Tampa
On March 17, PMI U.S. announced an investment of about USD 50 million in a new Business Solutions Center in Tampa, Florida. The center is expected to create about 180 direct and indirect high-skilled jobs and will consolidate business solutions, distribution operations and customer service into one hub.
Mar.18 by 2FIRSTS.ai
Russia’s Volgograd fines retailer 300,000 rubles for unlabelled nicotine products, orders confiscation and destruction
Russia’s Volgograd fines retailer 300,000 rubles for unlabelled nicotine products, orders confiscation and destruction
Volgograd, Russia say a retailer was caught selling unlabelled nicotine products, including electronic nicotine delivery devices flagged in the national “Honest Sign” tracking system as already withdrawn from circulation. A local court fined the entrepreneur 300,000 rubles and ordered 41 confiscated items to be destroyed, with the decision now in effect.
Feb.05 by 2FIRSTS.ai
BAT says a U.S. import block on some disposable vapes could cut illegal sales by about a third
BAT says a U.S. import block on some disposable vapes could cut illegal sales by about a third
Reuters reported that British American Tobacco (BAT) CEO Tadeu Marroco said a potential U.S. move to block imports of some disposable vapes could reduce the market for unregulated e-cigarettes by as much as a third, though any impact is unlikely before 2027.
Feb.13 by 2FIRSTS.ai
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
During FDA’s Feb 10 PMTA roundtable (manufacturing controls panel), small ENDS manufacturers warned that uncertainty in manufacturing expectations creates existential financial risk. FDA officials reiterated review flexibility is constrained by statutory and scientific boundaries. The panel debated testing standards, documentation requirements, open-system responsibility, supply chain changes, and software updates—highlighting unresolved PMTA challenges for small manufacturers.
Feb.11